Literature DB >> 17649988

Structure-activity relationship study on N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinehexanamides, a class of 5-HT7 receptor agents. 2.

Marcello Leopoldo1, Enza Lacivita, Marialessandra Contino, Nicola A Colabufo, Francesco Berardi, Roberto Perrone.   

Abstract

Here we report the synthesis of N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinealkylamides 16-29 that were designed to elucidate both structure-affinity and -activity relationships for the 5-HT7 receptor, by targeting the substituent in 2-position of the aryl linked to the piperazine ring. The affinities of 16-29 for 5-HT7, 5-HT1A, 5-HT2A, and D2 receptors were assessed by radioligand binding assays. The intrinsic activities at the 5-HT7 receptor of the most potent compounds were determined. A series of substituents covering a wide range of electronic, steric, and polar properties was evaluated, revealing a key role on 5-HT7 receptor affinity and intrinsic activity. Certain lipophilic substituents (SCH3, CH(CH3)2, N(CH3)2, CH3, Ph) led to high-affinity agonists, whereas OH and NHCH3 substituents switched intrinsic activity toward antagonism. 4-[2-(1-Methylethyl)phenyl]-N-(1,2,3,4-tetrahydronaphthalen-1-yl)-1-piperazinehexanamide (19), 4-(2-diphenyl)-N-(1,2,3,4-tetrahydronaphthalen-1-yl)-1-piperazinehexanamide (21), and 4-(2-dimethylaminophenyl)-N-(1,2,3,4-tetrahydronaphthalen-1-yl)-1-piperazinehexanamide (22) were identified as potent 5-HT7 receptor agonists (Ki = 0.13-1.1 nM, EC50 = 0.90-1.77 microM), showing selectivity over 5-HT1A, 5-HT2A, and D2 receptors.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17649988     DOI: 10.1021/jm070487n

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  13 in total

Review 1.  Serotonin 5-HT7 receptor agents: Structure-activity relationships and potential therapeutic applications in central nervous system disorders.

Authors:  Marcello Leopoldo; Enza Lacivita; Francesco Berardi; Roberto Perrone; Peter B Hedlund
Journal:  Pharmacol Ther       Date:  2010-10-20       Impact factor: 12.310

2.  5-HT1D receptors inhibit the monosynaptic stretch reflex by modulating C-fiber activity.

Authors:  Ana M Lucas-Osma; Yaqing Li; Katie Murray; Shihao Lin; Sophie Black; Marilee J Stephens; Andrew H Ahn; C J Heckman; Keith K Fenrich; Karim Fouad; David J Bennett
Journal:  J Neurophysiol       Date:  2019-01-09       Impact factor: 2.714

3.  Polysynaptic excitatory postsynaptic potentials that trigger spasms after spinal cord injury in rats are inhibited by 5-HT1B and 5-HT1F receptors.

Authors:  Katherine C Murray; Marilee J Stephens; Michelle Rank; Jessica D'Amico; Monica A Gorassini; David J Bennett
Journal:  J Neurophysiol       Date:  2011-06-08       Impact factor: 2.714

4.  Motoneuron excitability and muscle spasms are regulated by 5-HT2B and 5-HT2C receptor activity.

Authors:  Katherine C Murray; Marilee J Stephens; Edmund W Ballou; Charles J Heckman; David J Bennett
Journal:  J Neurophysiol       Date:  2010-10-27       Impact factor: 2.714

5.  Activation of 5-hyrdoxytryptamine 7 receptors within the rat nucleus tractus solitarii modulates synaptic properties.

Authors:  Michael P Matott; David D Kline
Journal:  Brain Res       Date:  2016-01-15       Impact factor: 3.252

6.  Towards metabolically stable 5-HT7 receptor ligands: a study on 1-arylpiperazine derivatives and related isosters.

Authors:  Enza Lacivita; Paola De Giorgio; Daniela Patarnello; Mauro Niso; Nicola A Colabufo; Francesco Berardi; Roberto Perrone; Grzegorz Satala; Beata Duszynska; Andrzej J Bojarski; Marcello Leopoldo
Journal:  Exp Brain Res       Date:  2013-04-10       Impact factor: 1.972

7.  Assessment of 5-HT(7) Receptor Agonists Selectivity Using Nociceptive and Thermoregulation Tests in Knockout versus Wild-Type Mice.

Authors:  Alex Brenchat; Maria Rocasalbas; Daniel Zamanillo; Michel Hamon; José Miguel Vela; Luz Romero
Journal:  Adv Pharmacol Sci       Date:  2012-06-19

Review 8.  Targeting the Serotonin 5-HT7 Receptor in the Search for Treatments for CNS Disorders: Rationale and Progress to Date.

Authors:  Agnieszka Nikiforuk
Journal:  CNS Drugs       Date:  2015-04       Impact factor: 5.749

9.  The arylpiperazine derivatives N-(4-cyanophenylmethyl)-4-(2-diphenyl)-1-piperazinehexanamide and N-benzyl-4-(2-diphenyl)-1-piperazinehexanamide exert a long-lasting inhibition of human serotonin 5-HT7 receptor binding and cAMP signaling.

Authors:  Patricio Atanes; Enza Lacivita; Javier Rodríguez; José Brea; Javier Burgueño; José Miguel Vela; María Isabel Cadavid; María Isabel Loza; Marcello Leopoldo; Marián Castro
Journal:  Pharmacol Res Perspect       Date:  2013-12-05

10.  Acute 5-HT7 receptor activation increases NMDA-evoked currents and differentially alters NMDA receptor subunit phosphorylation and trafficking in hippocampal neurons.

Authors:  Maryam S Vasefi; Kai Yang; Jerry Li; Jeff S Kruk; John J Heikkila; Michael F Jackson; John F MacDonald; Michael A Beazely
Journal:  Mol Brain       Date:  2013-05-14       Impact factor: 4.041

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.